Global Burden of Disease 2016. Lower respiratory infections collaborators, estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1191–210.

Article  Google Scholar 

Centers for Disease Control and Prevention. Chapter 11: Pneumococcal, manual for the surveillance of vaccine-preventable diseases. 2020. https://www.cdc.gov/vaccines/pubs/surv-manual/chpt11-pneumo.html. Accessed 2023 May.

Ogilvie I, Khoury AE, Cui Y, et al. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine. 2009;27(36):4891–904.

Article  PubMed  Google Scholar 

Said MA, Johnson HL, Nonyane BA, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS ONE. 2013;8(4):e60273.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pelton SI, Bornheimer R, Doroff R, et al. Decline in pneumococcal disease attenuated in older adults and those with comorbidities following universal childhood PCV13 immunization. Clin Infect Dis. 2019;68(11):1831–8.

Article  CAS  PubMed  Google Scholar 

Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015;70(10):984–9.

Article  PubMed  Google Scholar 

Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among US adults: updated recommendations of the advisory committee on immunization practices-United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Merck & Co., Inc., Rahway, NJ, USA. Safety and immunogenicity of V116 in pneumococcal vaccine-naïve adults (V116-003, STRIDE-3). 2022. https://classic.clinicaltrials.gov/show/NCT05425732. Accessed Mar 2024.

Centers for Disease Control and Prevention. Active bacterial core surveillance report, emerging infections program network, Streptococcus pneumoniae, 2020. 2020. Atlanta, GA: Centers for Disease Control and Prevention.

Centers for Disease Control and Prevention. Active bacterial core surveillance report, emerging infections program network, Streptococcus pneumoniae, 2019. 2019. Atlanta, GA: Centers for Disease Control and Prevention.

Centers for Disease Control and Prevention. 2016–2021 serotype data for invasive pneumococcal disease cases by age group from active bacterial core surveillance. 2023. Atlanta, GA: Centers for Disease Control and Prevention.

Bureau of Labor Statistics. CPI for all urban consumers (CPI-U): medical care in U.S. city average, all urban consumers, not seasonally adjusted. 2023. Bureau of Labor Statistics.

United States Census Bureau. Annual estimates of the resident population by single year of age and sex for the United States: April 1, 2020 to July 1, 2021. 2022; https://www.census.gov/data/datasets/time-series/demo/popest/2020s-national-detail.html. Accessed Mar 2024.

Arias E, Xu JQ. United States life table, 2019, in National Vital Statistics Report. 2022. Hyattsville, MD: National Center for Health Statistics (USA).

Balsells E, Dagan R, Yildirim I, et al. The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: a systematic review and meta-analysis. J Infect. 2018;77(5):368–78.

Article  PubMed  Google Scholar 

Dasbach EJ, Elbasha EH. Verification of decision-analytic models for health economic evaluations: an overview. Pharmacoeconomics. 2017;35(7):673–83.

Article  PubMed  Google Scholar 

Owusu-Edusei K, Deb A, Johnson KD. Estimates of the health and economic burden of pneumococcal infections attributable to the 15-valent pneumococcal conjugate vaccine serotypes in the USA. Infect Dis Ther. 2022. https://doi.org/10.1007/s40121-022-00588-x.

Article  PubMed  PubMed Central  Google Scholar 

Huang LP, Wasserman M, Grant L, et al. Burden of pneumococcal disease due to serotypes covered by the 13valent and new higher-valent pneumococcal conjugate vaccines in the United States. Vaccine. 2022;40(33):4700–8.

Article  CAS  PubMed  Google Scholar 

Stoecker C, Kim L, Gierke R, Pilishvili T. Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older in the United States. J Gen Intern Med. 2016;31(8):901–8.

Article  PubMed  PubMed Central  Google Scholar 

Chen C, Wood J, Beutels P, et al. The role of timeliness in the cost-effectiveness of older adult vaccination: a case study of pneumococcal conjugate vaccine in Australia. Vaccine. 2018;36(10):1265–71.

Article  CAS  PubMed  Google Scholar 

Leidner A. Summary of three economic models assessing pneumococcal vaccines in US adults. Atlanta, GA: Advisory Committee on Immunization; 2021.

Leidner AJ, Murthy N, Chesson HW, et al. Cost-effectiveness of adult vaccinations: a systematic review. Vaccine. 2019;37(2):226–34.

Article  PubMed  Google Scholar 

Treskova M, Scholz SM, Kuhlmann A. Cost effectiveness of elderly pneumococcal vaccination in presence of higher-valent pneumococcal conjugate childhood vaccination: systematic literature review with focus on methods and assumptions. PharmacoEconomics. 2019;37(9):1093–127.

Article  PubMed  Google Scholar 

Deb A, Guggisberg P, Mutschler T, et al. Cost-effectiveness of the 15-valent pneumococcal conjugate vaccine for high-risk adults in Switzerland. Expert Rev Vaccines. 2022;21(5):711–22.

Article  CAS  PubMed  Google Scholar 

Cho BH, Stoecker C, Link-Gelles R, Moore MR. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions. Vaccine. 2013;31(50):6011–21.

Article  PubMed  Google Scholar 

Stoecker, C. Economic analysis of sustaining the current recommendation for PCV13 use among adults 65 years or older in the context of continued indirect effects from the pediatric PCV13 program. Presented at the Advisory Committee on Immunization Practices. Meeting (2018 October 24 : Atlanta, GA). October 24, 2018. https://stacks.cdc.gov/view/cdc/61452. Accessed on March 2024.

Stoecker C. Economic analysis of sustaining the current recommendation for PCV13 use among adults 65 years or older in the context of continued indirect effects from the pediatric PCV13 program. 2019. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pneumococcal-05-Stoecker-508.pdf. Accessed 2019 June.

Stoecker C. Economic assessment of PCV15 & PCV20. Presentation to the ACIP June 25, 2021. 2021. Centers for Disease Control and Prevention.

Stoecker C. Economic assessment of PCV20 for adults vaccinated with PCV13. Presented at ACIP, October 19, 2022. 2022. Centers for Disease Control and Prevention.

Stoecker C, Hampton LM, Link-Gelles R, et al. Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine. Pediatrics. 2013;132(2):e324–32.

Article  PubMed  Google Scholar 

Stoecker C, Hampton LM, Moore MR. 7-Valent pneumococcal conjugate vaccine and otitis media: effectiveness of a 2-dose versus 3-dose primary series. Vaccine. 2012;30(44):6256–62.

Article  CAS  PubMed  Google Scholar 

Stoecker C, Kobayashi M, Matanock A, Cho BH, Pilishvili T. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program. Vaccine. 2020;38(7):1770–7.

Article  PubMed  Google Scholar 

Wateska AR, Nowalk MP, Lin CJ, et al. Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50–64 years compared to the US general population. Vaccine. 2019;37(14):2026–33.

Article  PubMed  PubMed Central  Google Scholar 

Wateska AR, Nowalk MP, Lin CJ, et al. Cost-effectiveness of pneumococcal vaccination policies and uptake programs in us older populations. J Am Geriatr Soc. 2020;68(6):1271–8.

Article  PubMed  PubMed Central  Google Scholar 

Wateska AR, Nowalk MP, Lin CJ, et al. Pneumococcal vaccination in adults aged >/=65 years: cost-effectiveness and health impact in U.S. populations. Am J Prev Med. 2020;58(4):487–95.

Article  PubMed  PubMed Central  Google Scholar 

Wateska AR, Nowalk MP, Lin CJ, et al. Cost-effectiveness of pneumococcal vaccination and uptake improvement programs in underserved and general population adults aged < 65 Years. J Community Health. 2020;45(1):111–20.

Article  PubMed  PubMed Central  Google Scholar 

Wateska AR, Nowalk MP, Lin CJ, et al. Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults. Vaccine. 2023;41(30):4431–7.

Article  PubMed  Google Scholar 

Wateska AR, Nowalk MP, Zimmerman RK, Smith KJ, Lin CJ. Cost-effectiveness of increasing vaccination in high-risk adults aged 18–64 Years: a model-based decision analysis. BMC Infect Dis. 2018;18(1):52.

Article  PubMed  PubMed Central  Google Scholar 

Wateska AR, PatriciaNowalk M, Lin CJ, et al. Cost-effectiveness of revised US pneumococcal vaccination recommendations in underserved minority adults < 65-years-old. Vaccine. 2022;40(50):7312–20.

Article  PubMed  PubMed Central  Google Scholar 

Stoecker C. Economic assessment of PCV15 & PCV20. Presented at ACIP. June 15, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/03-Pneumococcal-Stoecker-508.pdf. Accessed Mar 2024.

Rubin JL, McGarry LJ, Strutton DR, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine. 2010;28(48):7634–43.

Article  PubMed  Google Scholar